OncoMatch/Clinical Trials/NCT06841354
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Is NCT06841354 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for triple negative breast neoplasms.
Treatment: Sacituzumab tirumotecan · Pembrolizumab · Rescue Medication · Paclitaxel · Nab-paclitaxel · Gemcitabine · Carboplatin — Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Triple-Negative Breast Cancer
Breast Carcinoma
Biomarker criteria
Excluded: PD-L1 (CD274) expression
Has TNBC with evaluable tumor programmed death ligand 1 (PD-L1) expression at combined positive score (CPS) ≥10
Prior therapy
Cannot have received: systemic therapy for locally recurrent unresectable or metastatic breast cancer
Has received prior systemic therapy for treatment of locally recurrent unresectable or metastatic breast cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USA Mitchell Cancer Institute ( Site 0090) · Mobile, Alabama
- Ironwood Cancer & Research Centers ( Site 0036) · Chandler, Arizona
- City of Hope ( Site 0097) · Duarte, California
- City of Hope Lennar Foundation Cancer Center ( Site 0099) · Irvine, California
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047) · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06841354 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic therapy for locally recurrent unresectable or metastatic breast cancer disqualifies patients from enrollment.
Are patients with CD274 alterations eligible?
No. CD274 expression is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify